Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 29, 2021New England Journal of MedicineOpen Access

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

View Full Paper
Ask AI
Bookmark
Share

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

A 2021 study studied this question.

synapsesocial.com/papers/6a7d0516e9cd826fb346c874https://doi.org/10.1056/nejmoa2105290
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study2021 · 603 citations
  2. 2Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study2021 · 1,398 citations
  3. 3Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials2020 · 116 citations
  4. 4Thrombocytopenia following Pfizer and Moderna <scp>SARS‐CoV</scp>‐2 vaccination2021 · 393 citations
  5. 5A strategic approach to COVID-19 vaccine R&amp;D2020 · 545 citations